Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral PTH (1-34) in Hypoparathyroidism
NCT02152228Phase 2Completed
- Sponsor
- Entera Bio Ltd.
- Start
- Jul 2014
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teriparatide in hypoparathyroidism, sponsored by Entera Bio Ltd. Primary endpoints: Number of participants with adverse events at 17 weeks, Reduction in use of exogenous calcium supplement and/or alpha D3 supplement at 17 weeks and 3 more. Started Jul 2014; status: completed.
02
Drugs
teriparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT02152228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152228.